An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Patients With Myeloid Malignancies
A Phase 1a/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BG-75202, Alone and in Combination With Other Agents, in Patients With Myeloid Malignancies
- Myeloid Malignancy
At a glance
- Phase
- Phase 1
- Study type
- Interventional
- Sponsor
- BeOne Medicines
- Enrolment target
- 118
- Started
- 23 June 2026
- Main results due
- 30 September 2028
- Study sites
- 17
- Registry updated
- 28 September 2026
Can you take part?
- Aged 18 years and over.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria: * Patients must be ≥ 18 years of age (or the legal age of consent in the jurisdiction in which the study is taking place), inclusive, at the time of signing the Informed consent form (ICF). * Patients must have a confirmed diagnosis of myeloid malignancies based on 2016 World Health Organization criteria, and meet the following categories: * Relapsed/refractory; myeloid malignancies after ≥1 prior systemic therapy, per ELN; 2022 criteria; patients with actionable genetic alteration must have previously received targeted therapies unless contraindicated, unavailable/inaccessible, or declined by patient. * Patients must have a stable Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2. Exclusion Criteria: * Prior exposure to KAT6A/B inhibitors/degraders. * A diagnosis of acute promyelocytic leukemia or BCR-ABL-positive leukemia. * Known central nervous system involvement by leukemia * Use of antileukemic therapies without sufficient washout period Note: Other protocol defined Inclusion/Exclusion criteria may apply.
What this study is about
In the sponsor’s own words, from the registry.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of BG-75202 (KAT6A/B inhibitor) alone and in combination with other agents in patients with myeloid malignancies.
Study sites(17)
Concord Repatriation General Hospital
Concord, New South Wales, Australia
Recruiting
St George Hospital
Kogarah, New South Wales, Australia
Recruiting
Icon Cancer Centre Kurralta Park
Kurralta Park, South Australia, Australia
Recruiting
Barwon Health the Geelong Hospital
Geelong, Victoria, Australia
Recruiting
Austin Health
Heidelberg, Victoria, Australia
Recruiting
Linear Clinical Research
Nedlands, Western Australia, Australia
Recruiting
The First Hospital of Lanzhou University
Lanzhou, Gansu, China
Recruiting
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, China
Recruiting
The Second Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
Recruiting
The First Affiliated Hospital of Zhengzhou Universitysouth Branch
Zhengzhou, Henan, China
Recruiting
Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, China
Recruiting
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Recruiting
The First Affiliated Hospital of Nanchang University Branch Donghu
Nanchang, Jiangxi, China
Recruiting
The First Affiliated Hospital of Nanchang University Branch Xianghu
Nanchang, Jiangxi, China
Recruiting
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciencestuanbo Branch
Tianjin, Tianjin Municipality, China
Recruiting
North Shore Hospital
Auckland, New Zealand
Recruiting
Auckland City Hospital
Auckland, New Zealand
Recruiting
Showing 17 of 17 sites. 17 of the 17 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT07619287. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me